Oral anabolic steroid
Turinabol
Turinabol (dehydrochloromethyltestosterone, DHCMT) is an oral anabolic-androgenic steroid; a 1991 study in male volunteers reported a terminal half-life of 16 hours for the unchanged compound after intravenous dosing.
Turinabol after one dose: 50% at ~16 h, 25% at 32 h, 12.5% at 48 h.
Drawn from the half-life in the app's model, ~16 h. The model's figures
- Compound
- Turinabol
- Symbol
- TBL
- Family
- Other steroids
- Parts
- 13
- References
- 17
- Checked
- Last reviewed . Sources are listed below.
Overview
Sources in this part
Dehydrochloromethyltestosterone (DHCMT), marketed as Oral Turinabol, is an anabolic-androgenic steroid that Loke and colleagues, in the Journal of Steroid Biochemistry and Molecular Biology in 2021, describe as developed by Jenapharm in the 1960s.1 A 2026 review in German by Spitzer and Bley states that the most frequently used doping substances in the German Democratic Republic were anabolic-androgenic steroids, especially dehydrochlormethyltestosterone, which was also approved as a medicine under the trade name Oral-Turinabol.2
Reports of the compound in people include a 1984 series of 20 patients given 5 or 10 mg a day by mouth, a 1991 pharmacokinetic study in male volunteers and a 2021 controlled administration of 5 mg to five volunteers.3,4,1 A search of PubMed on 16 November 2026 for turinabol, dehydrochloromethyltestosterone, chlorodehydromethyltestosterone, its long chemical name or DHCMT in the title or summary text returned 54 records, and a search of ClinicalTrials.gov for turinabol and for dehydrochloromethyltestosterone returned 0 studies each. The other records include urine metabolite and detection studies, laboratory enzyme experiments and case reports.
The figures at the top are the app's: a half-life of about 16 hours, bioavailability of 95%, time to peak of about 2 hours and a typical dose of 10 to 60 mg a day by mouth. The sections below set the figures reported in the studies beside them.
How it works
In a 1991 study in male volunteers, Schumann wrote that, due to its affinity to sex hormone-binding globulin (SHBG), the compound is able to compete for the protein binding of testosterone, resulting in an increased plasma level of non protein-bound testosterone.4 A search of PubMed on 16 November 2026 combining the compound names with aromatase, aromatization, aromatisation or androgen receptor in the title or summary text returned 0 records, and the sources cited here report no androgen receptor binding or aromatization data for it.
Metabolism in people
Dürbeck and colleagues, in the Journal of Chromatographic Science in 1983, studied the free fraction of human urine after administration of the compound and reported three major metabolites, 6 beta-hydroxy-turinabol, 6 beta, 12-dihydroxy-turinabol and 6 beta, 16-dihydroxy-turinabol.5 They wrote that no measurable amounts of the unchanged compound were detected in any of the urine samples investigated, and that the total amount recovered, in the form of the three main metabolites, is on the order of 15%.5 Sobolevsky and Rodchenkov, of the Moscow Antidoping Centre, fractionated urine pooled from several samples that tested positive for the compound, reported that about 50 metabolites were found, and in 2012 identified and tentatively characterized 6 new long-term metabolites.6
Laboratory enzyme experiments
In laboratory experiments, not in people, Schiffer and colleagues at Saarland University reported in 2016 that the human mitochondrial enzymes CYP11A1, CYP11B1 and CYP11B2 converted the compound, whereas microsomal steroid hydroxylases did not.7 They also reported that all three enzymes are inhibited by the compound in their natural function, with the strongest effect for CYP11B2.7 In a 2021 laboratory study, Putkaradze and colleagues reported that the human brain enzyme CYP46A1 converted the compound to 16β-hydroxy oral turinabol and that the compound competed with cholesterol for the enzyme's active site in vitro, which they wrote "might be of importance for potential pathogenic effects of oral turinabol".8
Pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~16 h
- Bioavailability
- 95%
- Typical dose
- 10–60 mg/day
- Route
- Oral
- Time to peak
- ~2 h
Sources in this part
The table sets the app's figures beside those reported in Schumann's 1991 study, which gave single oral and intravenous doses of tritium-labelled compound to male volunteers.4
| Parameter | The app's figure | Reported in the sources |
|---|---|---|
| Half-life | ~16 hours | Terminal half-life of 16 h for the unchanged compound after intravenous administration, with biphasic disposition; the summary text gives no half-life after oral dosing.4 |
| Bioavailability | ~95% | No percentage is given. Schumann wrote that the compound is "almost completely absorbed" after 10 mg orally, and also that oral dosing is "subject to a first-pass effect, resulting in a diminished systematic availability".4 |
| Time to peak | ~2 hours | Peak plasma concentrations of total radioactivity and of the compound were reached "about 3 h p.a.".4 |
| Duration of activity | ~1.5 days (36 hours) | No duration of activity is reported in the sources cited here. |
| Route | Oral | Single oral and intravenous doses in Schumann's study; oral in the studies of Vogel and Loke; applied to the skin as part of a mixture in the study of Gessner.4,3,1,9 |
| Urinary excretion | Not listed in the app | Urinary total radioactivity was about 60% of the dose after both oral and intravenous administration, and the compound and its metabolites are preferentially excreted via the kidneys.4 |
The chart is an illustration from the app's figures, not measured concentrations. It applies the app's half-life of 16 hours, which matches an intravenous terminal value in Schumann's 1991 study, and time to peak of 2 hours, where that study reports about 3 h, to a chosen dose up to 60 mg, although the studies cited here give no dose above 10 mg a day.4 The only interval offered is the daily dosing reported by Vogel and colleagues.3
Level over 1 weeks
Level, as a share of the peak after one 10 mg dose
As studied: every day3.
An illustration from a pharmacokinetic model using a half-life of 16 hours. It is not a measured level or a suggested dose.
Human studies
The table lists studies that report people given the compound, a mixture containing it, or a history of taking it, and none has a placebo group in the summary text cited here.
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Schumann, 19914 | Pharmacokinetic study of single oral and intravenous doses of tritium-labelled compound; sponsor not stated in the PubMed record | Male volunteers; number not stated in the PubMed record | 10 mg orally per volunteer; intravenous dose not stated in the record | Terminal half-life 16 h after intravenous dosing, peak about 3 h, about 60% of the dose in urine as total radioactivity, marked enterohepatic circulation. |
| Vogel and colleagues, 19843 | Patients treated with the compound; no comparator group described and sponsor not stated in the PubMed record | 20 patients with established insufficient fibrinolysis | 5 or 10 mg per day orally; results reported to the 3rd and 4th months | Fibrinolytic capacity began to increase four weeks after the start and peaked in the 3rd and 4th months; roughness of the voice in two patients, slight weight gain in one. |
| Loke and colleagues, 20211 | Controlled administration with urine collected for 60 days; no comparator group described; no grant listed, and the PubMed record types the work as research supported by a non-US government source | 5 healthy male volunteers | 5 mg orally, one dose; urine for 60 days | Metabolite M3 was a suitable long-term marker in four volunteers and detectable for 45 days in one; M5 gave longer detection in two; in one volunteer M3 was undetectable and M2 was the longest detectable metabolite; the last clearly positive sample was collected between 9.9 and 44.9 days. |
| Gessner and colleagues, 20229 | Application to the skin in dimethylsulfoxide; urine at 1 h, 6 h and daily for 14 days; sponsor not stated in the PubMed record | 12 male subjects; half received oxandrolone alone and half a mixture of four steroids that included the compound | Amount not stated in the PubMed record; urine for 14 days | Substances or their metabolites were detectable in some cases within hours and for up to 10 to 14 days, with inter-individual variability in detection windows, variation between substances and a possible impact of skin location; the summary text gives no result for the compound alone. |
| Berger and colleagues, 202410 | Cross-sectional, retrospective comparison of three groups; no specific grant declared | 159 people: 55 former adolescent athletes who received AAS in the former GDR, 50 athletes without doping and 54 people not active in sport | Doses and duration not reported in the text cited; 41 of the 55 reported use of oral turinabol | Hepatopathy 25.5% in the doping group against 4% or 8.2% and 1% or 1.9% in the comparison groups; arrhythmia 34.5% against 8.2% in both comparison groups; arterial hypertension 38.2% against 17% in the athletes without doping; higher risk also for tumor diseases (OR = 4.0) and depression (OR = 9.2) against the athletes without doping. |
Deeper analysis: Schumann's 1991 pharmacokinetic study
Schumann, at the Institut für Mikrobiologie und experimentelle Therapie in Jena, published the pharmacokinetic study in Die Pharmazie in 1991.4 Plasma concentrations of total radioactivity and of the unchanged drug, and urinary excretion, were estimated after single oral and intravenous doses, and the parameters were calculated model-independently from statistical moments.4 Schumann attributed irregularities in the plasma profile after both routes to "a marked enterohepatic circulation", and reported an AUC ratio of unchanged drug to total radioactivity of 1 : 13, which "shows the predominance of metabolites in plasma".4 The PubMed record carries the summary text only, so the number of volunteers, the intravenous dose, any funder, any conflict statement and any limitations stated by the author are not given in the text cited here.4
Deeper analysis: Loke and colleagues' 2021 controlled administration
Loke and colleagues, with affiliations at the Freie Universität Berlin and the Laboratorio Antidoping FMSI in Rome, wrote that "no controlled administration trial monitoring these long-term metabolites was reported until now".1 Five healthy male volunteers took 5 mg by mouth, urine was collected for 60 days, and the unconjugated and glucuronidated fractions were analysed separately by gas chromatography coupled to tandem mass spectrometry.1 The authors reported that the metabolite epiM4 was identified in the urine of all volunteers, and that "Due to interindividual differences there were several varieties in the excretion profiles among the volunteers".1 The PubMed record lists no grant and no conflict statement but types the work as "Research Support, Non-U.S. Gov't", and the summary text reports no adverse events, hormone or blood measurements, or other health outcomes.1
Deeper analysis: Berger and colleagues' 2024 comparison of former GDR athletes
Berger and colleagues, in the Department of Orthopaedic Surgery at Otto-von-Guericke University Magdeburg, interviewed people who presented as outpatients for an orthopaedic examination, and the participants also completed standardized psychological tests.10 In the doping group, 41 reported use of oral turinabol, 28 of dynvital and 15 of athletovit, which the paper describes as supplements mixed with mestanolone, and 14 reported injections with doping substances.10 The paper reports a higher risk of hepatopathy for the doped individuals than for group II, the athletes without doping (OR = 3.8, p = 0.036), and for group III, the people not active in sport (OR = 17.8), so the finding is for the whole doping exposure and not for oral turinabol alone.10 On limitations the authors wrote that "Despite its piloting character, the present study has a few caveats, as it is cross-sectional and retrospective in nature, and relies on a restricted sample", and concluded that the effects "might not only be due to the side effects of these substances but also caused by the system".10 The paper states that the authors "have not declared a specific grant for this research"; one author, C.H. Lohmann, lists company affiliations for presentations and study support (Implantec GmbH, MathysMedical and W. Link GmbH Co. KG), and the other six authors declare no conflict of interest.10
Doses reported in studies
| Study | Dose and route | People | Length |
|---|---|---|---|
| Schumann, 19914 | 10 mg orally per volunteer; intravenous dose not stated in the PubMed record | Male volunteers | Single doses |
| Vogel and colleagues, 19843 | 5 or 10 mg per day orally | 20 patients | Results reported to the 3rd and 4th months of treatment |
| Loke and colleagues, 20211 | 5 mg orally, one dose | 5 healthy male volunteers | Urine collected for 60 days |
| Gessner and colleagues, 20229 | Applied to the skin in dimethylsulfoxide; amount not stated in the PubMed record | 12 male subjects, half of them given a mixture that included the compound | Urine collected for 14 days |
| Froehner and colleagues, 199911 | "High dose" Oral-Turinabol; amount and route not stated in the PubMed record | 1 man, reported at age 32 | A 5-year history of use that began at age 18 and stopped about 9 years before presentation |
Berger and colleagues' text reports that 41 of 55 former adolescent athletes took oral turinabol but gives no dose.10 The doses stated in these studies are 5 mg once, 10 mg once and 5 or 10 mg a day, and none states 60 mg a day, the top of the app's typical range of 10 to 60 mg a day.
Side effects reported
In Vogel and colleagues' series of 20 patients given 5 or 10 mg a day, the side effects listed were roughness of the voice in two patients and slight weight gain in one patient.3 In one patient with thrombotic tendency, the tendency disappeared under medication and appeared anew after the drug was withdrawn.3
Case reports
Froehner and colleagues, at the Technical University of Dresden, reported in Cancer in 1999 a 32-year-old man with an intratesticular leiomyosarcoma who reported a 5-year history of systematic use of high dose Oral-Turinabol that began at age 18 and stopped approximately 9 years before presentation.11 The authors wrote that the findings "support the hypothesis that high dose doping with androgenic anabolic steroids could have played a cocarcinogenic role in the development of the tumor in this case".11 Daniels and colleagues, in the Nederlands Tijdschrift voor Geneeskunde in 2006, described a 34-year-old bodybuilder with massive rhabdomyolysis who had used tablets and injections containing dehydro-chloro-methyltestosterone, boldenone and trenbolone, together with clenbuterol, liothyronine and phosphatidylcholine.12 He recovered quickly and his renal function remained unaffected, and the report cannot separate the effect of one agent from the others.12
Observational findings and laboratory reports
In Berger and colleagues' comparison of former GDR athletes, the differences were gender-specific, with males in the doping group more often having impaired liver function, depression, tumors and difficulties associated with the workplace, while significant increases in musculoskeletal diseases (spinal syndromes, arthropathies, osteopathies, myopathies) were found in females and not in males, and the doping group's exposure included oral turinabol, supplements mixed with mestanolone and injections.10 In the laboratory experiments described above, the compound inhibited the natural function of three human steroid-synthesizing enzymes and competed with cholesterol at CYP46A1, and these are laboratory results, not results in people.7,8 Schumann's and Loke's summary texts report no adverse events.4,1
Bloodwork and markers
Sources in this part
The app lists liver enzymes, lipids and hematocrit as markers for the compound. The studies cited here measured fibrinolytic capacity in patients, plasma radioactivity and urinary metabolites in volunteers, and Schumann wrote that SHBG binding results in an increased plasma level of non protein-bound testosterone, without stating that the level was measured.3,4,1 None of the cited sources reports a lipid or hematocrit result for the compound, and the liver finding is Berger and colleagues' reported hepatopathy in the doping group, taken from histories and not from enzyme measurements in the text cited.10
Regulatory and anti-doping status
The WADA Prohibited List 2026, in effect from 1 January 2026, names dehydrochlormethyltestosterone in section S1.1, anabolic androgenic steroids, "When administered exogenously, including but not limited to" the listed substances.13 Class S1 is "PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)" and its substances are non-Specified Substances.13 The United States Code definition of an anabolic steroid in 21 U.S.C. 802(41)(A) lists dehydrochloromethyltestosterone among the substances it includes.14 The sources cited here include no drug regulator's label or assessment document for the compound.
Testing and detection findings
Kolliari-Turner and colleagues, in Sports Medicine in 2021, reported that exogenous anabolic androgenic steroid metabolites were present in 90% of the 142 athlete samples from IOC re-tests, with dehydrochloromethyltestosterone and stanozolol accounting for 79% of detected substances.15 A 2021 report on weightlifting by Kolliari-Turner and colleagues in Sports Medicine - Open stated that targeted re-analysis of 2008 and 2012 Olympic samples resulted in 61 weightlifters producing retrospective anti-doping rule violations, and that dehydrochloromethyltestosterone and stanozolol accounted for 83% of detected substances and were present in 95% of these samples.16 Loke and colleagues wrote that long-term metabolites proposed in 2011 and 2012 "resulted in adverse analytical findings in retests of the Olympic games of 2008 and 2012".1 Geyer and colleagues reported in 2008 that since 2002 nutritional supplements faked with high amounts of classic anabolic steroids, including dehydrochloromethyltestosterone, had been detected, and that these steroids were not declared on the labels.17
What is not known
Sources in this part
A search of PubMed on 16 November 2026 for the compound names with trial, randomized, randomised or placebo in the title or summary text returned 1 record, the 2021 controlled administration to five volunteers, and the ClinicalTrials.gov search returned 0 studies.1 The sources cited here give no oral half-life, no percentage for oral bioavailability, no duration of activity and no dose above 10 mg a day, so the app's figures for those are not matched by a source. The sources cited here report no measured effect of the compound on muscle mass, strength, lipids or hematocrit in people, and the human findings above come from small or uncontrolled series, case reports and one cross-sectional comparison.
Frequently asked questions
What is Turinabol?
Turinabol is the name for dehydrochloromethyltestosterone (DHCMT), an anabolic-androgenic steroid marketed as Oral Turinabol.1
What is the half-life of Turinabol?
Is Turinabol banned by WADA?
How long can Turinabol be detected in urine?
In Loke and colleagues' 2021 study of five volunteers who each took a single 5 mg oral dose, the last sample clearly identified as positive was collected between 9.9 and 44.9 days.1 One metabolite, M3, was detectable for 45 days in one volunteer and undetectable in another, and the authors reported interindividual differences in the excretion profiles.1
How long does it take Turinabol to peak?
The app lists a time to peak of about 2 hours, and Schumann's 1991 study reported that peak plasma concentrations of total radioactivity and of the compound were reached "about 3 h p.a."; the summary text does not name the route for that peak and gives 10 mg orally as the oral dose.4
What is the bioavailability of Turinabol?
What dose of Turinabol was used in studies?
What side effects of Turinabol have been reported?
In a series of 20 patients given 5 or 10 mg a day, Vogel and colleagues reported roughness of the voice in two patients and slight weight gain in one patient, and in one patient with thrombotic tendency the tendency disappeared under medication and appeared anew after the drug was withdrawn.3 A 1999 case report described an intratesticular leiomyosarcoma in a man with a 5-year history of high dose Oral-Turinabol use, and the authors wrote that doping could have played a cocarcinogenic role in that case.11 A 2024 cross-sectional comparison of former GDR athletes reported hepatopathy in 25.5% of the doping group and arrhythmia in 34.5%, against lower rates in the comparison groups, for the whole doping exposure and not for oral turinabol alone.10 A 2006 case report described massive rhabdomyolysis in a bodybuilder who had used dehydro-chloro-methyltestosterone together with boldenone, trenbolone and other drugs, and who recovered quickly.12
Has Turinabol been tested in clinical trials?
A search of ClinicalTrials.gov on 16 November 2026 for turinabol and for dehydrochloromethyltestosterone returned 0 studies each. A search of PubMed on the same date for the compound names with trial, randomized, randomised or placebo in the title or summary text returned 1 record, the 2021 controlled administration to five volunteers.1 The human studies listed above include a series of 20 patients treated with the compound (Vogel and colleagues, 1984) and single-dose studies in volunteers (Schumann, 1991, and Loke and colleagues, 2021), and the searches above cover only the terms and fields stated.3,4,1
Is Turinabol listed in United States anabolic steroid law?
Yes, the United States Code definition of an anabolic steroid in 21 U.S.C. 802(41)(A) lists dehydrochloromethyltestosterone among the substances it includes.14
Guides, tools and comparisons
References
- Loke S, et al. Controlled administration of dehydrochloromethyltestosterone in humans: urinary excretion and long-term detection of metabolites for anti-doping purpose. J Steroid Biochem Mol Biol 2021. PMID 34418529
- Spitzer C, Bley B. State-sponsored doping in GDR elite sport: health consequences, reappraisal, and questions of legal compensation (in German). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2026. PMC13323326
- Vogel G, Huyke R, Lauten G. Modification of hypofibrinolytic states by dehydrochlormethyltestosterone. Folia Haematol Int Mag Klin Morphol Blutforsch 1984. PMID 6083927
- Schumann W. The pharmacokinetics of Oral-Turinabol in humans. Pharmazie 1991. PMID 1798729
- Dürbeck HW, et al. GC and capillary column GC/MS determination of synthetic anabolic steroids. II. 4-chloro-methandienone (oral turinabol) and its metabolites. J Chromatogr Sci 1983. PMID 6630400
- Sobolevsky T, Rodchenkov G. Detection and mass spectrometric characterization of novel long-term dehydrochloromethyltestosterone metabolites in human urine. J Steroid Biochem Mol Biol 2012. PMID 22142641
- Schiffer L, et al. Metabolism of Oral Turinabol by human steroid hormone-synthesizing cytochrome P450 enzymes. Drug Metab Dispos 2016. PMID 26658226
- Putkaradze N, et al. Metabolism of oral turinabol by the human brain cholesterol 24-hydroxylase CYP46A1. J Steroid Biochem Mol Biol 2021. PMID 34089835
- Gessner L, Thevis M, Rothschild MA, Jübner M. Detectability of oxandrolone, metandienone, clostebol and dehydrochloromethyltestosterone in urine after transdermal application. Drug Test Anal 2022. PMID 35947101
- Berger K, et al. Long-term effects of doping with anabolic steroids during adolescence on physical and mental health. Orthopadie (Heidelb) 2024. PMC11329390
- Froehner M, et al. Intratesticular leiomyosarcoma in a young man after high dose doping with Oral-Turinabol: a case report. Cancer 1999. PMID 10526287
- Daniels JM, et al. Rhabdomyolysis in a bodybuilder using steroids. Ned Tijdschr Geneeskd 2006. PMID 16733985
- World Anti-Doping Agency. Prohibited List 2026 (in effect 1 January 2026). WADA list
- United States Code, Title 21, section 802(41): definition of anabolic steroid (Cornell Legal Information Institute). 21 U.S.C. 802
- Kolliari-Turner A, et al. Analysis of anti-doping rule violations that have impacted medal results at the Summer Olympic Games 1968-2012. Sports Med 2021. PMID 33835351
- Kolliari-Turner A, et al. Doping practices in international weightlifting: analysis of sanctioned athletes/support personnel from 2008 to 2019 and retesting of samples from the 2008 and 2012 Olympic Games. Sports Med Open 2021. PMID 33415428
- Geyer H, et al. Nutritional supplements cross-contaminated and faked with doping substances. J Mass Spectrom 2008. PMID 18563865